Xencor

Xencor

Yahoo Finance • yesterday

Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?

Biotech stocks offered a mixed third-quarter bag on Thursday, with Arcutis reversing and BeOne Medicines surging deeper into its buy zone. Continue Reading... Full story

Yahoo Finance • 12 days ago

Xencor reports promising kidney cancer drug results, plans late-stage trial

[Doctor with cancer patient] Ridofranz/iStock via Getty Images Xencor (XNCR [https://seekingalpha.com/symbol/XNCR]) reported encouraging results from an early-stage clinical trial of its experimental kidney cancer drug XmAb819, with tumor... Full story

Yahoo Finance • last month

Raymond James Updates Healthcare Top Picks for October

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeu... Full story

Yahoo Finance • 2 months ago

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.

You probably know Johnson & Johnson (NYSE: JNJ) mainly for its prescription medications. Some may be familiar with the company's medical devices. But J&J has another role that many people may not know about: It's a healthcare investor. Jo... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 4 months ago

Xencor advances 17% after revealing ESMO 2026 oral presentation slot

[antibody in pink and red background selective focus 3d art] mirror-images/iStock via Getty Images Shares of Xencor (XNCR [https://seekingalpha.com/symbol/XNCR]) surged 17% on Friday, rising $2.52 to close at $17.47. The move came after t... Full story

Yahoo Finance • 5 months ago

Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial

[Incyte headquarters in Wilmington, Delaware, USA] JHVEPhoto/iStock Editorial via Getty Images Incyte’s (INCY [https://seekingalpha.com/symbol/INCY]) immunotherapy Monjuvi, developed with Xencor (XNCR [https://seekingalpha.com/symbol/XNCR... Full story

Yahoo Finance • 6 months ago

Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential

Company Logo Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and rising investment, it’s vita... Full story

Yahoo Finance • 7 months ago

Stocks Settle Lower as Iran War Boosts Crude Oil and Bond Yields

The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.18%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.77%.  June E-mini S&P futures (ESM26) fell -0.35%, and J... Full story

Yahoo Finance • 7 months ago

Stocks Fall as Iran War Drags On

The S&P 500 Index ($SPX) (SPY) today is down -0.16%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.50%.  June E-mini S&P futures (ESM26) are down -0.174%, and June E-mini Nas... Full story

Yahoo Finance • 7 months ago

Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades: Citi upgraded Ralph Lauren(RL) to Buy fr... Full story

Yahoo Finance • last year

Xencor Stock Earns Relative Strength Rating Upgrade

A Relative Strength Rating upgrade for Xencor shows improving technical performance. Will it continue? Continue Reading View Comments... Full story

Yahoo Finance • last year

Xencor slides amid plans for early-stage trial data for kidney cancer drug

[Cancer cell view] Xencor (NASDAQ:XNCR [https://seekingalpha.com/symbol/XNCR]) shares lost ~13% on Tuesday as the company refuted concerns over an upcoming data readout from an early-stage trial for its kidney cancer drug, XmAb819, schedu... Full story

Yahoo Finance • last year

We Did The Math RWJ Can Go To $54

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • last year

Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts

[Wall Street New York stock exchange stock market] alexsl Erasca (NASDAQ:ERAS [https://seekingalpha.com/symbol/ERAS]), Candel Therapeutics (NASDAQ:CADL [https://seekingalpha.com/symbol/CADL]), and Xencor (NASDAQ:XNCR [https://seekingalpha... Full story

Yahoo Finance • last year

Xencor appoints biotech veteran Raymond Deshaies to board of directors

PASADENA, Calif. - Xencor, Inc. (NASDAQ:XNCR) announced Thursday the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies previously served as senior vice president of global research at Amgen Inc., where he o... Full story

Yahoo Finance • last year

Xencor director Montgomery sells shares worth $20,422

Montgomery Alan Bruce, a director at Xencor Inc (NASDAQ:XNCR), recently sold shares of the company amounting to $20,422. The transaction, which took place on June 16, 2025, involved the sale of 2,215 shares at a price of $9.22 each. This... Full story

Yahoo Finance • last year

Xencor director Gustafson sells shares worth $27,595

PASADENA, CA— Xencor Inc (NASDAQ:XNCR) Director Kurt A. Gustafson sold 2,993 shares of the company’s common stock on June 16, 2025, at an average price of $9.22 per share, totaling $27,595. The sale comes as Xencor’s stock trades near its... Full story

Yahoo Finance • 2 years ago

Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago

We think intelligent long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example, after five long years the Xencor, Inc. (NASDAQ:XNCR) share price is a whole 52% lower. That is extremely sub-op... Full story

Yahoo Finance • 3 years ago

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

PASADENA, Calif., November 21, 2023--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases,... Full story